LABT
Lakewood-Amedex Biotherapeutics Inc.Company Information
- Company Name
- Lakewood-Amedex Biotherapeutics Inc.
- CIK
- CIK0002079272
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- LABT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LABT
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -17.18%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|
| Related Party | - | 0 | ||||||
Assets Current | ||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 0 | ||||||
| Short Term Investments | 2 | - | ||||||
| Interest Receivable Current | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | ||||||
| Assets Current | 5 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | ||||||
| Assets | 5 | 0 | ||||||
Liabilities Current | ||||||||
| Accounts Payable Current | 0 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 0 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | ||||||
| Liabilities Current | 1 | 3 | ||||||
| Operating Lease Liability Noncurrent | - | 0 | ||||||
| Liabilities | 1 | 3 | ||||||
Stockholders Equity | ||||||||
| Common Stock Value | 0 | 0 | ||||||
| Additional Paid In Capital | 73 | 52 | ||||||
| Retained Earnings Accumulated Deficit | -69 | -54 | ||||||
| Treasury Stock Value | -0 | -0 | ||||||
| Stockholders Equity | 4 | -3 | ||||||
| Liabilities And Stockholders Equity | 5 | 0 | ||||||
| Series A Convertible Preferred Stock | 0 | 0 | ||||||
| Series B Convertible Preferred Stock | 0 | 0 | ||||||
| Series C Convertible Preferred Stock | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 13 | 125 | ||||||
| Common Stock Shares Issued | 2 | 7 | ||||||
| Shares Outstanding | 2 | 7 | ||||||
| Treasury Stock Common Shares | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLakewood-Amedex Biotherapeutics Inc. (LABT) — SEC Financial Statements & Analysis
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a pharmaceutical preparations company, incorporated in NV. Lakewood-Amedex Biotherapeutics Inc. trades on Nasdaq as: LABT. Lakewood-Amedex Biotherapeutics Inc. (LABT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Lakewood-Amedex Biotherapeutics Inc. carries a market cap of $4.46M, a P/B ratio of 1.03x, and an enterprise value of $1.87M. On the balance sheet, it maintains a current ratio of 7.70x, a quick ratio of 7.30x, working capital of $4.22M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, and net debt of $-2.58M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.46M
- P/B TTM
- 1.03x
- Debt To Equity
- 0.15x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lakewood-Amedex Biotherapeutics Inc. in?
Lakewood-Amedex Biotherapeutics Inc. (LABT) operates in the Pharmaceutical Preparations industry.
What exchange does LABT trade on?
Lakewood-Amedex Biotherapeutics Inc. (LABT) trades on the Nasdaq.
Where is Lakewood-Amedex Biotherapeutics Inc. incorporated?
Lakewood-Amedex Biotherapeutics Inc. is incorporated in NV.
When was Lakewood-Amedex Biotherapeutics Inc. (LABT)'s most recent SEC filing?
Lakewood-Amedex Biotherapeutics Inc. (LABT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is LABT's market cap?
Lakewood-Amedex Biotherapeutics Inc. (LABT) has a market capitalization of $4.46M as of 2026-06-30.